Tafamidis for the Treatment of Transthyretin Amyloid Cardiomyopathy
Tafamidis costs PACE organizations an estimated $240,000 per participant annually. This webinar will provide an overview of the financial and clinical aspects of prescribing tafamidis, and its use in the treatment of transthyretin amyloid cardiomyopathy. PACE executive directors/CEOs, CFOs, medical directors, prescribers, and clinical pharmacists are invited to attend this webinar, which will include a panel discussion.
Register Now
Learning objectives:
- Review the pathophysiology of transthyretin amyloid cardiomyopathy
- Describe the mechanism of action of tafamidis
- Discuss and analyze the findings of the ATTR-ACT trial
- Assess the cost-effectiveness of tafamidis
- Determine the potential place in therapy for tafamidis
Presenter:
Selina Muhn, PharmD, Pharmacy Practice Resident, PGY1, Research and Development, Tabula Rasa HealthCare
Panel Discussion Guests:
Mathew S. Maurer, MD, Geriatric Cardiologist, Medical Director, HCM Center, New York-Presbyterian Hospital/Columbia University Medical Center
Frederick Ruberg, MD, Cardiologist Associate Professor, Medicine and Amyloidosis Center at Boston University School of Medicine
